DRL gets final nod from USFDA for Fondaparinux

July 14, 2011 01:05 am | Updated 01:05 am IST - HYDERABAD:

Dr. Reddy's Laboratories and Brisbane-based Alchemia Limited have announced that Dr. Reddy's received final approval for its ANDA for Fondaparinux Sodium injection, a bioequivalent generic version of Arixtra, by the U.S. Food and Drug Administration.

The approval would cover 2.5 mg/0.5 mL, 5 mr/0.4 mL, 7.5 mg/0.6mL and 10 mg/0.8 mL doses of the drug in prefilled colour-coded single dose syringes with automatic needle safety device.

DRL would manufacture Fondaparinux using a patented process developed by Alchemia, according to a release.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.